<DOC>
	<DOCNO>NCT01370005</DOCNO>
	<brief_summary>This trial evaluate safety efficacy BI 10773 hypertensive patient type 2 diabetes . Since hyperglycaemia hypertension key risk factor micro- macrovascular complication , assessment glucose blood pressure lower effect BI 10773 hypertensive patient type 2 diabetes could provide clinically highly relevant , new information use BI 10773</brief_summary>
	<brief_title>12 Week Efficacy Safety Study Empagliflozin ( BI 10773 ) Hypertensive Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients &gt; =18 year type 2 diabetes 2 . HbA1c &gt; = 7.0 % ( 53 mmol/mol ) = &lt; 10 % ( 86 mmol/mol ) 3 . Mean seat systolic blood pressure 130159 mmHg diastolic blood pressure 8099 mmHg Exclusion criterion : 1 . Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) overnight fast randomization 2 . Known suspected secondary hypertension 3 . Acute coronary syndrome ( nonSTEMI , STEMI unstable angina pectoris ) , stroke transient ischemic attack within 3 month prior inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>